NVO Mar 2025 165.000 call
| Previous close | 8.50 |
| Open | 8.70 |
| Bid | 8.40 |
| Ask | 8.75 |
| Strike | 165.00 |
| Expiry date | 2025-03-21 |
| Day's range | 8.60 - 8.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 394 |
GlobeNewswireNovo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia A
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8 Bagsværd, Denmark, 23 June 2024 – Novo Nordisk announced results from the phase 3 FRONTIER2 trial of 254 adults and adolescents aged 12 years and over with haemophilia A, with and without inhibitors. The trial assessed both once-weekly and once-monthly prophylactic treatment (regular treatment to prevent prolonged and spontaneous bleeding) w
Fool.co.ukI just put £4k into my SIPP. Here’s where I’m going to invest it
Edward Sheldon's been contributing to his SIPP to build wealth for retirement. Here’s a look at where he’s investing his money. The post I just put £4k into my SIPP. Here’s where I’m going to invest it appeared first on The Motley Fool UK.
ZacksNovo Nordisk (NVO) Gains As Market Dips: What You Should Know
In the most recent trading session, Novo Nordisk (NVO) closed at $140.99, indicating a +0.13% shift from the previous trading day.
